Objective: This study aimed to investigate the relationship between serum adipokine levels and gynecological malignancies.

Materals and Methods: Ethical approval was received for the study from the non-interventional studies ethics committee of a university hospital. Two groups of 38 patients, each histopathologically diagnosed with gynecological malignancy, and 38 healthy volunteers were formed. Height, weight, Body Mass Index (BMI), tumor markers Carcinoembryonic antigen (CEA) and Cancer antigen 125 (CA-125) were measured for all groups. In addition, serum adipokine speksin, sprosin, metrnl and kisspeptin levels from blood samples were studied by ELISA method. The results were compared statistically.

Results: Of the patients included in the study, 63.2% had ovarian cancer, 28.9% had endometrial cancer, 5.3% had cervical cancer, and 2.6% had vulvar cancer. The average age of those in the patient group was 57.1±15.6 and that of those in the control group was 52.5±13.1 (p=0.162). There were no significant differences between the groups in terms of height (p=0.785), weight (p=0.433) and BMI (p=0.383). CEA (p=0.045) and CA -125 (p<0.001) values of the patient group were significantly higher than the control group. Kisspeptin (p<0.001), metrnl (p<0.001) and asprosin (p<0.001) values of the patient group were significantly lower than the control group. There was no significant difference between the groups in terms of spexin molecule (p=0.308).

Conclusions: Serum adipokine levels vary in gynecological malignancies. While serum asprosin, kisspeptin and metrnl levels are lower in gynecological malignancies, there is no change in spexin levels.